The University of Nantes

National Institute of Health and Medical Research

Centre Hospitalier Universitaire De Nantes

Other

Inserm

Aboleris Pharma

Carole Guillonneau

Ignacio Anegon

Severine Bezie

Séverine Bezie

Elodie Picarda

Erwan Mortier

Sandrine Bezie

MUTATED INTERLEUKIN-34 (IL-34) POLYPEPTIDES AND USES THEREOF IN THERAPY

Disclosed is a method for obtaining a population of human Treg cells including the steps of: (a) culturing a population of human monocytes with a medium including an amount of an interleukin-34 (IL-34) polypeptide in order to obtain a population of immunosuppressive macrophages; (b) co-culturing a population of human peripheral blood mononuclear cells (PBMCs) and the population of immunosuppressive macrophages obtained at step (a).

Methods for obtaining regulatory t cells and uses thereof

The invention relates to an isolated interleukin-34 (IL-34) polypeptide for use in preventing or treating graft rejection, autoimmune disease, unwanted immune response against therapeutic proteins and allergy. The invention also provides an in vitro method for determining whether a patient is at risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies, comprising a step of determining the expression level of IL-34 in a biological sample obtained from said patient, wherein the presence of IL-34 is indicative of a reduced risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies.

Isolated interleukin-34 polypeptide for use in preventing transplant rejection and treating autoimmune diseases

Pharmaceutical composition comprising IL-34 and a mTOR inhibitor

Methods for obtaining regulatory T cells and uses thereof

Disclosed is a method for labeling, detecting and/or isolating Foxp3+ Treg cells from a biological sample containing peripheral blood mononuclear cells (PBMC) or lymphocytes including the following steps of: (i) coupling the surface of PBMC or lymphocytes to a capture moiety which binds to the cell through a cell surface molecule and to interleukin-34 (IL34), (ii) culturing the lymphocytes under conditions wherein IL34 is secreted, released and specifically captured by the capture moiety, (iii) labeling the IL34 expressing lymphocytes with a label moiety, and (iv) optionally detecting and/or isolating the IL34 expressing lymphocytes which are Foxp3+ Treg cells. Also disclosed is an isolated population of Foxp3+ Treg cells obtainable by the method and uses thereof.

Methods and kits for labeling, detection and isolation of Foxp3regulatory T cells, isolated population of Foxp3regulatory T cells thus obtained and uses thereof

Method for inhibiting or reducing transplant rejection by adminstration of interleukin-34

The invention relates to an peptide derived from a polymorphic region of donor MHC class II molecules which induces tolerance and thus prevents transplant rejection in a patient in need thereof. The invention relates to isolated peptide of length ranging between 11 and 16 amino acids comprising the amino acid sequence: SDVGEYR (SEQ ID NO: 1) or a function-conservative variant thereof for use as drug. The invention relates to an in vitro method for determining whether a transplanted patient is tolerant, comprising a step of determining the presence of CD8+CD45RCTregs in a biological sample obtained from said transplanted patient, wherein the presence of CD8CD45RCTregs is indicative of tolerance.

Isolated donor MHC-derived peptide and uses thereof

The invention relates to an peptide derived from a polymorphic region of donor MHC class II molecules which induces tolerance and thus prevents transplant rejection in a patient in need thereof. The invention relates to an isolated peptide of 15 or 16 amino acids long that comprises or consists of the amino acid sequence: REEYARFDSDVGEYR (SEQ ID NO: 1) or a function-conservative variant for use as drug. The invention relates to an in vitro method for determining whether a transplanted patient is tolerant, comprising a step of determining the presence of CD8CD45RCTregs in a biological sample obtained from said transplanted patient, wherein the presence of CD8CD45RCTregs is indicative of tolerance.

Growing community of inventors

Nantes, France

Carole Guillonneau